Biosimilar Guidance Silent On Industry's Biggest Questions

By Rachel Slajda (February 10, 2012, 9:27 PM EST) -- The U.S. Food and Drug Administration's newly released guidance on how it will review biosimilars was a relief to an industry that's been waiting two years for clarity. But experts say the guidance is quiet on the details that will determine just how pricey biosimilar development will be.

Biosimilars, the generic versions of biological drugs, have the potential to become a multibillion-dollar industry in the U.S. But in the two years since Congress authorized the FDA to approve biosimilars, the agency has received zero applications for biosimilar approval.

That is due, in part, to a lack of concrete information from the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!